Advisory Board

Dr. Nicholas Plotnikoff, Non-Executive Chairman

Dr. Plotnikoff has a Ph.D. in pharmacology, with over 20 years of experience in the pharmaceutical industry, having worked in pharmacology, toxicology, and clinical research. He was a professor of pharmacology at the University of Illinois Medical Center in Chicago and played a pioneering role in investigations of the immunological effects of MENK. Dr. Plotnikoff also successfully managed the project teams that developed the NDAs on Traxene (a Valium-like tranquilizer) and Cylert (a non-amphetamine psychostimulant). In basic research, he was the first to identify the central nervous system effects of hypothalamic-releasing factors (brain hormones), resulting in their clinical development for treatment of depression and Parkinson’s disease. Dr. Plotnikoff has co-authored 25 publications with Dr. Andrew Schally, covering basic research in the fields of depression and Parkinson’s disease, and held a number of international patents for the use of MENK in HIV/AIDS and cancer. He is further credited with achieving major breakthroughs in the treatment of certain cancers and of HIV/AIDS. Along with the late Dr. Bernard Bihari (see page xx), Dr. Plotnikoff completed Phase I and early Phase II clinical trials in the U.S. using MENK, and has collaborated with Dr. Joseph Wybran from Belgium on clinical trials for treatment by MENK in patients with HIV/AIDS. Trials continue in China with the support of China Medical University and Professor Shan using MENK, which began in 2007 (as described on page xx). Immune Therapeutics is now partnering with Professor Shan on treating cancer patients with IRT-101 and IRT-102 in China.

Dr. Jill Smith, MD

Dr. Jill Smith, an Advisor to the company, is a former Professor of Medicine in the Gastroenterology Division of the Department of Medicine, Hershey Medical Center, Penn State University. Dr. Smith has a long track record of conducting pre-clinical scientific research as well as translational clinical trials in patients. Over the course of her twenty-two years at Penn State University, she has mentored thirty-eight post-doctoral Fellows and students, thereby ensuring continuing excellence in medicine for future generations.

Dr. Smith’s research focus is on disorders of the gastrointestinal tract and pancreas. In her role as a Professor in the College of Medicine’s Internal Medicine Department she treats patients with Inflammatory Bowel Diseases.

Simultaneously, in her role as Professor of Cellular and Molecular Physiology she teaches and conducts basic science research in the graduate school. For over two decades, Dr. Smith has conducted industry-sponsored trials and investigator-initiated research involving inflammatory bowel disease. One of her areas of expertise is in translational medicine.

Another area of expertise for Dr. Smith involves her research on pancreatic cancer. Dr. Smith’s team discovered that growth of pancreatic cancer is controlled by a small protein called gastrin. They further discovered a novel receptor on human pancreas cancer through which gastrin exerts its effects. Dr. Smith’s discovery led to her being the recipient of the Basic Science Research Award, a prestigious award given by the European Pancreas Society for outstanding discoveries in science. Ongoing research using this novel receptor or targeting therapy and early detection of pancreatic cancer is underway. Dr. Smith is also is a co-discoverer of the role of another protein called OGF (Opioid Growth Factor) that inhibits growth of pancreatic cancer. This discovery has been confirmed in both Phase 1 and Phase 2 clinical trials treating patients with advanced pancreatic cancer with OGF.

Dr. Smith was the first ever researcher to carry out a clinical trial of low dose naltrexone. The results of the successful trial in patients suffering from Crohn’s disease has spearheaded ongoing clinical trials by other researchers at several institutions worldwide.

Dr. Smith has been elected as the first woman President of the American Pancreas Association. For three years, she has served as the Chairman of the American Gastroenterology Association’s Research Committee and she currently serves on National Institutes of Health review panels for research grants.

Dr. Smith has chaired a National Cancer Institute workshop on pancreatic cancer and her expertise in pancreatic cancer and translational research has made her a sought-after international speaker in these fields.

Dr. Terry Grossman, M.D.

Dr. Grossman is the founder and medical director of the Grossman Wellness Center in Denver, Colorado. His longevity medical practice attracts patients, including many VIPs (such as coauthor Ray Kurzweil) from around the country and the world. He graduated from Brandeis University in 1968 and the University of Florida School of Medicine in 1979. He spent 15 years (from 1980-1995) working as a community family doctor in the Colorado mountains. Dr. Grossman undertook the study of nutritional and anti-aging medicine in 1994 and in 1995 opened the Grossman Wellness Center in Denver, which quickly grew into one of the largest complementary medical centers in the country. He is a member and board certified by the American Academy of Anti-Aging Medicine as well as the American Holistic Medical Association. His special field of interest is nutritional medicine (the treatment of illness with nutrients such as vitamins, minerals, anti-oxidants and natural hormones) and anti-aging medicine. Dr. Grossman is a widely sought lecturer on longevity medicine throughout the U.S. and has presented keynote addresses at anti-aging seminars in Japan, South Korea, South Africa, and elsewhere. He is the author of the Baby Boomers’ Guide to Living Forever (2000), and coauthor with Ray Kurzweil of Fantastic Voyage (2004), and TRANSCEND: Nine Steps to Living Well Forever (2009).

Dr. Clifford Selsky, MD

Dr. Selsky has been a practicing pediatrician in Central Florida for the past twenty years. He is the founder of the Children’s Center for Cancer and Blood Disease at Florida Hospital cancer institute, which he established after training in pediatrics at Yale New Haven hospital and completing a pediatric hematology and oncology fellowship at Yale University School of Medicine. Dr. Selsky is board certified in Pediatrics, Pediatric hematology and oncology and Palliative medicine. Currently, he is a pediatrician at Family First Pediatrics which he established in 2013.

Also an accomplished scientist, Dr. Selsky obtained his PH.D. in Microbiology and Molecular Genetics at the University of Miami School of Medicine. He then did DNA repair research studies at the radiobiology laboratory at Harvard School of Public Health and the biophysics laboratory at Stanford University. Dr. Selsky has numerous publications in peer reviewed journals relating to DNA repair and clinical conditions such as angiocentric lymphoma and chemotherapy related neurological disorders. As a toxicologist for Stauffer Chemical Company, he designed and implemented research on molecular dosimetry and genetic risk estimation, including DNA adduct separation and quantitation.

Over the course of his career, he has served as principal investigator for both the Pediatric Oncology Group at Florida Hospital Cancer Institute and the Children’s Oncology group at Florida Hospital overseeing more than 140 cooperative group protocols. He was department chair for Pediatrics at Florida Hospital for Children for seven years. Additionally, he has served on numerous committees including Florida Hospital Cancer Center Medical Advisory committee, Florida Hospital Ethics committee, Florida Hospital Quality Assurance committee and Florida Hospital Pharmacy and Therapeutics committee. Dr. Selsky was elected president of the Orange County Medical Society in 2016 and has received numerous awards including the Florida Hospital Medical Staff recognition Award for Excellence 2008 and being named Top Doctor, Orlando Magazine in 2001, 2005, 2006, 2007, 2008, 2009, 2010, 2011 and 2015.

Dr. Chalil,MD

Dr. Joseph M. Chalil MD, MBA, FACHE is an Adjunct Professor at Nova Southeastern University in Florida and the Chairman of Global Clinical Research and Trial Network of the American Association of Physicians of Indian Origin (AAPI). AAPI is the second largest physician organization in the US second only to AMA, and the largest ethnic medical organization in the country.

 

Formerly, a Physician Executive at Boehringer Ingelheim and a veteran of the U.S. Navy Medical Corps, Dr. Chalil is also board certified in healthcare management, and has been awarded Fellowship by the American College of Healthcare Executives, an international professional society of more than 40,000 healthcare executives who lead hospitals, healthcare systems and other healthcare organizations.

 

Dr. Chalil holds three US Patents, and his research includes Clinical Trial Management in Cystic Fibrosis, Multiple Myeloma, and publications in American Journal of Respiratory and Critical Care Medicine. Dr. Chalil is a Visiting Professor at various universities and board member of various companies.

Mak Jawadekar, Ph.D.

Mak Jawadekar, Ph.D., is an independent pharmaceutical industry consultant and currently serves on several U.S. and international company boards in scientific advisory and business management capacities. After completing his Ph.D. (Pharmaceutics) at the University of Minnesota, he started working at Pfizer, Inc., and his tenure was over 28 years in length until March 2010, when he opted to take an early retirement. Mak was a Director, R & D Portfolio Management & Performance with the World Wide R & D Division of Pfizer Inc. in Groton/New London, CT, where he was leading efforts in R&D benchmarking metrics for speed, quality and costs to enhance Pharmaceutical R&D productivity.

Mak also advised Pfizer’s R&D business on system solution approaches and best practices, and served as an advisor to Pfizer’s President of Global R&D on Asia-related strategic matters. Prior to that, he spent many years with Pfizer’s Pharmaceutical Sciences Group as a leader, where he held responsibility for Strategic Outsourcing of Drug Products activities and Drug Delivery Technology Assessment functions. Mak also managed strategic-level decisions on external alliances and collaborations, including partnerships, due diligence activities, and licensing and development. His extensive previous Bench R & D experience includes dosage form development/formulations/drug delivery R&D, clinical manufacturing, tech transfer and scale-up operations, and worked closely with Pfizer Global Manufacturing and Consumer Health care divisions.